RNAV8 Bio Joins Team Selected for ARPA-H Funding to Develop Programmable RNA Medicines

PartnershipPROPEL programPositive

AI Analysis

Summary

RNAV8 Bio received ARPA-H pilot funding of up to $4.4 million over one year for the PROPEL program to develop logic-gated RNA therapies that control gene expression through RNA structure without genome alteration.

Outcome Details

ARPA-H pilot award for programmable RNA medicines development

Importance:6/10

Sentiment:

0.60

RNA therapeuticsARPA-H fundingprogrammable medicinepartnershipsgovernment funding

Related Companies

$STTK

Read the original article

Published by PR Newswire Pharma on September 1, 2026 1:00 PM

Read Original